Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Faculdade de Medicina do ABC | OTHER |
Not provided
Not provided
This study is a prospective, single-arm, open-label, multi-center, feasibility study to evaluate the safety and efficacy of the ColubrisMX ELS System in patients undergoing transanal endoluminal procedures, specifically colorectal Endoscopic Submucosal Dissection.
Endoscopic resection of small polyps is performed routinely through conventional outpatient colonoscopy. Larger polyps or incipient tumors can be excised with endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD). These minimally invasive procedures have been shown to be viable alternatives to conventional surgical resections with less risk of complications, shorter hospital stay and lower costs.
Both flexible endoscopic and open/laparoscopic surgical approaches have procedural limitations that can have considerable impact on patient care. Traditional endoscopic tools have technical inadequacies that may inhibit the physician's ability to complete more complex tasks consistent with a surgical technique. Conversely, a traditional open or laparoscopic surgical approach involves increased risk of complications (such as surgical site infection), increased pain and blood loss, longer recovery, and surgical scars. The objective of this clinical study is to assess the safety and efficacy of the ColubrisMX Endoluminal Surgical (ELS) System, a new robotic technology designed to assist the physician with precision, flexibility, and control during endoluminal removal of colorectal lesions.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Robotic Transanal Endoluminal Resection | Experimental | Robotic Transanal Endoluminal Resection of Colorectal Lesions |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ColubrisMX Endoluminal Surgical (ELS) System | Device | Robotic Transanal Endoluminal Resection of Colorectal Lesions using the ColubrisMX Endoluminal Surgical (ELS) System |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of success (%) | Percentage of patients with no conversion during surgery and no major complications (Clavien-Dindo ≥ III complication rating) for 24 hours post-op. | 24 hours post-op |
| Rate of conversions (%) | Percentage of patients with a change in treatment plan to a conventional open or laparoscopic procedure. | Intraoperative |
| Estimated blood loss (mL) | Estimated amount of intraoperative blood loss (up to the point of needing transfusion). | Intraoperative |
| Operative time (min) | Duration from transanal insertion of the robotic flexible overtube to final removal of the flexible overtube from the anal verge. | Intraoperative |
| Patients requiring transfusion (%) | Percentage of patients requiring transfusion during surgery. | Intraoperative |
| Complication rate (%) | Percentage of patients having Clavien-Dindo ≥ III intraoperatively or postoperatively at Days 7, 30, or 60. | 60 Days |
| Readmission rate (%) | Percentage of patients with readmission that can be linked to colorectal submucosal dissection. | 60 Days |
| Major Adverse Events (MAE) during the first 60 days |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| En bloc resection rate (%) | Percentage of samples dissected en bloc, as assessed by the pathologist during postoperative assessment. | Intraoperative |
| Rate of positive surgical lateral margins (PSLM) (%) |
INCLUSION CRITERIA
All of the following criteria must be present to be eligible for the study:
EXCLUSION CRITERIA
Patients will be excluded from the study if any of the following criteria are present:
Preoperative
Intraoperative
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Eduardo Grecco, MD | Faculdade de Medicina do ABC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculdade de Medicina do ABC | Santo André | São Paulo | 09060-870 | Brazil |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
| ID | Term |
|---|---|
| D016503 | Drug Delivery Systems |
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Freedom from procedural-related MAE, defined as a combined clinical endpoint of death or reoperation for failed surgical repair. |
| 60 Days |
The number and percentage of subjects with PSLM will be presented separately by subjects undergoing rectal ESD.
| 60 Days |
| Rate of perforations repaired operatively (%) | Rate of perforations requiring repair through open or laparoscopic surgery. | Intraoperative |
| Rate of perforations requiring repair through open or laparoscopic surgery (%) | Rate of perforations requiring repair through open or laparoscopic surgery | Intraoperative |
| Rate of delayed perforations (%) | Perforations that present 10 to 24 hours after procedure with clinical signs and symptoms of peritonitis. | 60 Days |
| Adverse Events | Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in patients, users, or other persons, whether related to the investigational medical device. | 60 Days |
| Vital Signs | Changes in vital signs from baseline to post-operative Days 7, 30 and 60. | 60 Days |
| Laboratory Assessments | Changes in laboratory parameters and normal/abnormal status changes in laboratory parameters from baseline to post-operative Days 7, 30 and 60. | 60 Days |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |